Pembrolizumab Biosimilar (Samsung Bioepis )

帕博利珠单抗生物类似药（Samsung Bioepis）

Report date: 2025/06/28 20:00:07

Base Information

Drug NamePembrolizumab Biosimilar (Samsung Bioepis )

Drug Alias NameSB27SB-27

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionProgrammed cell death protein 1 blockers

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBosnia and HerzegovinaPolandThailand +[15]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

ATC CodeL01XC18